arrow
S

Sunil Badve

Winship Cancer Institute
H指数:82
被引数:4.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

An Artificial Intelligence (AI) model integrating multiscale foundation model histopathology representations with molecular and clinical features predicts early and late distant recurrence in TAILORx

一种整合多尺度基础模型组织病理学表示与分子及临床特征的AI模型可预测TAILORx中的早期和晚期远处复发

2026-08-050
OAAI
Correction: Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy

修正:胸腺上皮肿瘤在免疫、自身免疫和免疫治疗交叉路口

2026-05-060
OAAI
Thymic epithelial tumors at the crossroads of immunity, autoimmunity, and immunotherapy

胸腺上皮肿瘤:免疫、自身免疫与免疫治疗的交汇点

2026-03-170
OAAI
A Global Ring Study: Concordance Between Ventana PATHWAY anti-HER2/neu (4B5) Companion Diagnostic Assay and Comparators in Detecting HER2-low Breast Cancer

全球环研究:Ventana PATHWAY anti-HER2/neu (4B5) 伴随诊断检测试剂盒与比较检测HER2低表达乳腺癌的一致性研究

2025-08-090
OAAI
Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration–Approved Benchmark

常用实验室开发测试方法与Ki-67在乳腺癌评估中的分析比较:以美国食品药品监督管理局批准的基准为例

2025-06-120
OA
Malignant phyllodes tumours of the breast: the case for revising WHO's 'full house' diagnostic criteria

乳腺恶性叶状肿瘤:修订世界卫生组织“全垒打”诊断标准的必要性

2025-04-010
OAAI
A Randomized Window of Opportunity Study of Preoperative Letrozole and Simvastatin Versus Letrozole Alone in Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
2024-05-020
PRE
Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112
2024-05-020
PRE
Scoring PD-L1 Expression in Urothelial Carcinoma: An International Multi-Institutional Study on Comparison of Manual and Artificial Intelligence Measurement Model (AIM-PD-L1) Pathology Assessments
2024-04-041
PRE
Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: First phase of a large-scale, multicenter global ring study
2024-03-220
PRE